약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 2.

Table. 2. Signal detection of GLP-1 RAs using disproportionality analysis in WHO-UMC VigiBase® from April 2005 to January 2023
Cases of GLP-1 RA Non-cases of GLP-1 RA ROR (95% CI) Signal
Biliary tract disorders*
America 122 158,002 1.29 (1.05-1.59) O
Europe 91 47,749 0.64 (0.51-0.79) X
Asia 19 9,019 1.41 (0.89-2.25) X
Other regions 1 1,552 0.81 (0.11-5.95) X
Gallbladder-related disorders*
America 396 157,728 2.34 (2.06-2.66) O
Europe 195 47,645 5.71 (4.62-7.05) O
Asia 44 8,994 4.12 (2.98-5.69) O
Other regions 6 1,547 2.32 (0.99-5.43) X

Abbreviations: ROR, Reporting Odds Ratio; CI, Confidence Interval; WHO-UMC, World Health Organization-Uppsala Monitoring Centre

*The Adverse Events of interest are defined using Standardized MedDRA Queries (SMQ)

Safety signals detection with ROR were assessed as AEs where thresholds of ROR were greater than one.

Yakhak Hoeji 2024;68:112-20 https://doi.org/10.17480/psk.2024.68.2.112
© 2024 Yakhak Hoeji